Novartis Submits More Info On Japan Diovan, Side-Effects Affair
This article was originally published in PharmAsia News
Executive Summary
Novartis's Japanese subsidiary has submitted further findings from investigations into the company’s involvement in physician-led clinical research and delays in reporting adverse events.